Ligand Pharmaceuticals | LGND - Operating Profit


Ligand Pharmaceuticals reported $158.89M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Agenus USD -13.31M 12.58M Mar/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD -4.28M 32.1M Mar/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Enviri Corporation USD 31.74M 5.63M Dec/2024
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
Insmed USD -249.71M 11.64M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
MacroGenics USD 18.64M 55.4M Sep/2025
Merck USD 6.24B 318M Dec/2025
Pacira USD 13.15M 2.92M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Veracyte USD 24.63M 1.52M Dec/2025